Eritrea

in page functions
[French]
Eritrea
Total population (2018) 5,616,784
Birth cohort (2018) 176,571
Surviving Infants (surviving to 1 year per year, 2018) 170,177
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 34/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 47/1000
World Bank Index, IDA (2015) 1.94
Gross Nation Income (per capita US$, 2011) 480
Co-financing group (2018) Initial self-financing
No. of districts/territories (2017) 58

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Eritrea

Type of support

Approvals

2001-2022 (US$)
(22 Jun 2018)

Commitments

2001-2022 (US$)
(22 Jun 2018)

Disbursements

2000-2018 (US$)
(22 Jun 2018)

% Disbursed

(22 Jun 2018)
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Total $28,450,087 $37,335,003 $25,554,368
Cold Chain Equipment Optimisation Platform (CCEOP) $970,534 $970,534
Health system strengthening (HSS 1) $2,778,000 $2,778,000 $2,778,000 100%
Health system strengthening (HSS 2) $4,319,209 $6,238,125 $2,399,708 56%
Immunisation services support (ISS) $436,540 $436,540 $436,540 100%
Injection Safety Devices (NVS) $96,000 $244,500 $125,171 130%
Injection safety support (INS) $148,029 $148,029 $148,029 100%
IPV (NVS) $227,567 $227,567 $119,067 52%
Measles (NVS) $239,197 $239,197 $248,024 104%
MR 1st and 2nd dose (NVS) $32,500 $398,000
MR-Catch-up campaign (NVS) $1,180,500 $1,180,500 $1,244,875 105%
MR-Catch-up campaign op.costs (OPC) $1,015,316 $1,015,316 $1,015,300 100%
Penta (NVS) $7,243,380 $8,291,380 $7,710,767 106%
Pneumo (NVS) $4,729,889 $8,722,389 $4,528,624 96%
Product Switch Grant (PSG) $31,841 $31,841 $31,841 100%
Rotavirus (NVS) $1,988,908 $3,400,408 $1,755,781 88%
Tetra DTP-HepB (NVS) $2,312,677 $2,312,677 $2,312,677 100%
Vaccine Introduction Grant (VIG) $700,000 $700,000 $699,964 100%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Eritrea DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2017)

Grade of confidence


N/A
DTP3 - Official country estimates (2017) 95%
M:F sex ratio at birth (2018) 1.05
Household survey: DTP3 coverage for male (2001) 81.60%
Household survey: DTP3 coverage for female (2001) 84.20%
Household survey: Last DTP3 survey (2007) 98%
% districts achieving > 80% DTP3 coverage (2017) 38%
% districts achieving < 50% DTP3 coverage (2017) 17%
MCV WHO/UNICEF estimates (2016) 93%

Breakdown of support

Non-vaccine support Vaccine support
29% 71%
$7,509,382 $18,044,986

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Eritrea

22 February 2016

Gavi item

Meningitis A nearly eliminated in Africa through vaccination

Joint press release first published by WHO and PATH, joint founders of the Meningitis Vaccine Project.

15 March 2013

Rt Hon Stephen O’Brien MP in Rwanda

Why I am a Red Nose Day supporter

I firmly believe that it is in the British character to try to help those whose lives are blighted by disease, poverty and violence. Red Nose Day, supported by Comic Relief, gives millions of people across the country the opportunity to do just that.

03 December 2012

MenAfriVac

100 millionth person receives lifesaving meningitis vaccine

A revolutionary meningitis vaccine will reach the 100 millionth person this week in a region of Africa that has been plagued by deadly epidemics for more than a century. The milestone will take place in northern Nigeria, part of Africa’s “meningitis belt’, where the country is conducting its second seasonal immunisation campaign against the disease.

close icon

modal window here